ISSN 1673-3770 CN 37-1437/R
Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2021, Vol. 35 ›› Issue (5): 75-84.doi: 10.6040/j.issn.1673-3770.0.2021.068
Previous Articles Next Articles
QI Wenwen1, CHEN Luqiu2, JIA Tao1, CHEN Xuemei1, ZHANG Jie1, ZHANG Hao1, JIN Peng1, ZHANG Hu3
CLC Number:
| [1] Makiyama K, Hirai R, Matsuzaki H, et al. Assessment of human Papilloma virus infection in adult laryngeal Papilloma using a screening test[J]. J Voice, 2013, 27(2):230-235. doi:10.1016/j.jvoice.2012.10.014. [2] 孙睿杰,许风雷,刘大昱,等.显微支撑喉镜下CO2激光手术或联合干扰素治疗复发性小儿喉乳头状瘤疗效对比[J].山东大学耳鼻喉眼学报, 2012, 26(6):23-25. doi:10.6040/j.issn.1673-3770.2012.06.008. SUN Ruijie, XU Fenglei, LIU Dayu, et al. Efficacy of CO2 laser surgery under microsupport laryngoscope or combined with interferon in the treatment of recurrent laryngeal papilloma in children[J]. J Otolaryngol Ophthalmol Shandong Univ, 2012, 26(6):23-25. doi:10.6040/j.Issn.1673-3770.2012.06.008. [3] Fortes HR, von Ranke FM, Escuissato DL, et al. Recurrent respiratory papillomatosis:a state-of-the-art review[J]. Respir Med, 2017,126:116-121. doi:10.1016/j.rmed.2017.03.030. [4] Langer C,Wittekindt C, Wolf G. Rezidivierende respiratorische Papillomatose: Aktuelles zu Diagnose und Therapie[J]. Onkologie Up2date, 2020, 2(2):107-118. doi:10.1055/a-1132-0051. [5] 申宇鹏,宋琦,李晓明.喉癌前病变的病因、分子机制和处理策略[J].山东大学耳鼻喉眼学报, 2019, 33(4):25-30. doi: 10.6040 /j.Issn.1673-3770.1.2019.029. SHEN Yupeng, SONG Qi, LI Xiaoming. Etiology, molecular mechanisms, and treatment strategies of precancerous laryngeal lesions[J]. J Otolaryngol Ophthalmol Shandong Univ, 2019, 33(4): 25-30. doi: 10.6040 /j.Issn.1673-3770.1.2019.029. [6] 张群慧,龚辉成,林颖,等.喉癌高危型人乳头状瘤病毒检测及表皮生长因子受体表达的研究[J].中国耳鼻咽喉头颈外科,2019,26(8):429-431. doi:10.16066/j.1672-7002.2019.08.007. ZHANG Qunhui, GONG Huicheng, LIN Ying, et al. Study of the detection of high risk HPV and EGFR expression in laryngeal cancer[J]. ChinArch Otolaryngol-Head Neck Surg, 2019, 26(8): 429-431. doi:10.16066/j.1672-7002.2019.08.007. [7] 雷文斌,刘其洪. CO2激光手术治疗复发性呼吸道乳头状瘤[J].山东大学耳鼻喉眼学报, 2018, 32(6):8-12. doi: 10.6040 /j.Issn.1673-3770.1.2018.014. LEI Wenbin, LIU Qihong. Progress in the treatment of recurrent respiratory papillomatosis using a CO2 laser[J]. J Otolaryngol Ophthalmol Shandong Univ, 2018, 32(6),32:8-12. doi: 10.6040 /j.Issn.1673-3770.1.2018.014. [8] 潘晓菲,王军,肖洋,等.LncRNA CTB-147C22.8 对复发性呼吸道乳头状瘤细胞侵袭的影响[J].山东大学耳鼻喉眼学报,2019,33(4):66-70. doi: 10.6040 /j.Issn.1673-3770.0.2018.409. PAN Xiaofei, WANG Jun, XIAO Yang, et al. Effect of lncRNA cTB-147C28.8 on the invasion of recurrent respiratory papilloma cells[J]. J Otolaryngol Ophthalmol Shandong Univ, 2019, 33(4):66-70. doi: 10.6040 /j.Issn.1673-3770.0.2018.409. [9] Reeves WC, Ruparelia SS, Swanson KI, et al. National registry for juvenile-onset recurrent respiratory papillomatosis[J]. Arch Otolaryngol-Head Neck Surg, 2003,129(9): 976-982. doi:10.1001/archotol.129.9.976. [10] Murali S, Saravanam PK, Dinakaran N. Role of Thuja in the management of laryngeal Papilloma[J]. BMJ Case Rep, 2020,13(12):e238846. doi:10.6040/j.Issn.1673-3770.0.2015.007. [11] 严羽,朱江.早期喉癌及喉癌前病变诊断的研究进展[J].山东大学耳鼻喉眼学报,2015,29(4):80-85. doi:10.6040 /j.issn.1673-3770.0.2015.007. SHEN Yupeng, SONG Qi, LI Xiaoming. Etiology, molecular mechanisms, and treatment strategies of precancerous laryngeal lesions[J]. J Otolaryngol Ophthalmol Shandong Univ, 2019, 33(4):25-30. doi:10.6040 /j.Issn.1673-3770.0.2015.007. [12] 张再兴,薛丽华.喉乳头状瘤的病因学机制及防治[J].山东大学耳鼻喉眼学报, 2005, 19(6): 409-411. doi:10.3969/j.issn.1673-3770.2005.06.024. ZHANG Zaixing, XUE Lihua[J]. J Otolaryngol Ophthalmol Shandong Univ,2005,19(6): 409-411. doi:10.3969/j.issn.1673-3770.2005.06.024. [13] Liu J, Yang T, Zhang Y, et al. Promotion of BZW2 by LINC00174 through miR-4500 inhibition enhances proliferation and apoptosis evasion in laryngealPapilloma[J]. Cancer Cell Int, 2020, 20:471. doi:10.1186/s12935-020-01559-3. [14] Lai EC. Two decades of miRNA biology: lessons and challenges[J]. RNA, 2015, 21(4):675-677. doi:10.1261/rna.051193.115. [15] Guo H, Qi RQ, Sheng J, et al. MiR-155, a potential serum marker of extramammary Paget's disease[J]. BMC Cancer, 2018, 18(1):1078. doi:10.1186/s12885-018-4994-1. [16] 徐颖誉.FADS2 rs3834458基因多态性与中国汉族人群非酒精性脂肪性肝病合并冠心病易感性研究[D].青岛:青岛大学,2019. doi:10.27262/d.cnki.gqdau.2019.001527. XU Yingyu. FADS2 rs3834458 gene polymorphism and susceptibility to non-alcoholic fatty liver disease complicated with coronary heart disease in Chinese Han population[D]. Qingdao: Qingdao University, 2019. doi:10.27262/d.cnki.gqdau.2019.001527. [17] Matsumoto A, Kawabata T, Kagawa Y, et al. Associations of umbilical cord fatty acid profiles and desaturase enzyme indices with birth weight for gestational age in Japanese infants[J]. Prostaglandins Leukot Essent Fatty Acids, 2021,165:102233. doi:10.1016/j.plefa.2020.102233. [18] 林智海,王正东,吴梓嘉,等.冠心病心绞痛患者倍他乐克联合阿司匹林治疗的有效性及对患者血清hs-CRP、sCD40L、IL-6水平的影响[J].临床和实验医学杂志, 2021, 20(3):259-262. doi:10.3969/j.Issn.1671-4695.2021.03.010. LIN Zhihai, WANG Zhengdong, WU Zijia, et al. Efficacy of betaloc combined with aspirin in patients with coronary heart disease and angina pectoris and its effect on serum hs-CRP, sCD40L and IL-6 levels[J]. Journal of Clinical and Experimental Medicine, 2021,20(3):259-262. doi:10.3969/j.Issn.1671-4695.2021.03.010. [19] 曹白鸽,刘冲霄,陈源文,等.IL-6上调SCD1表达对HepG2细胞脂质合成功能的影响[J]. 实用肝脏病杂志, 2019, 22(2):172-175. doi:10.3969/j.issn.1672-5069.2019.02.005. CAO Baige, LIU Chongxiao, CHEN Yuanwen, et al. Upregulation of SCD1 gene-related lipid synthesis by IL-6 stimulus in HepG2 cells in vitro[J]. J Pract Hepatol, 2019, 22(2):172-175. doi:10.3969/j.issn.1672-5069.2019.02.005. [20] Chen FD, Chen HH, Ke SC, et al. SLC27A2 regulates miR-411 to affect chemo-resistance in ovarian cancer[J]. Neoplasma, 2018,65(6): 915-924. doi:10.4149/neo_2018_180122n48. [21] Feng Y, Li S, Zhang R, et al. FOXM1 as a prognostic biomarker promotes endometrial cancer progression via transactivation of SLC27A2 expression[J]. Int J Clin Exp Pathol, 2018,11(8):3846-3857. doi:1936-2625/IJCEP0081131. [22] Dan C, Zhang HY, Zeng WJ, et al. HNF1B expression regulates ECI2 gene expression, potentially serving a role in prostate cancer progression[J]. Oncol Lett, 2019, 17(1):1094-1100. doi:10.3892/ol.2018.9677. [23] DeVoti JA, Rosenthal DW, Wu R, et al. Immune dysregulation and tumor-associated gene changes in recurrent respiratory papillomatosis: a paired microarray analysis[J]. Mol Med, 2008,14(9/10): 608-617. doi:10.2119/2008-00060.devoti. [24] 郭正平,张红.小儿喉乳头状瘤HPV感染与免疫功能变化的关系研究[J]. 华南国防医学杂志, 2020, 34(1):37-40. doi:10.13730/j.issn.1009-2595.2020.01.009. GUO Zhengping, ZHANG Hong. Correlation between HPV infection and immune function changes in children with laryngeal Papilloma[J]. Mil Med J South China, 2020, 34(1):37-40. doi:10.13730/j.issn.1009-2595.2020.01.009. [25] Sasaki E, Masago K, Fujita S, et al. Frequent KRAS and HRAS mutations in squamous cell papillomas of the head and neck[J]. J Pathol Clin Res, 2020, 6(2):154-159. doi:10.1002/cjp2.157. [26] Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020[J]. Rhinology, 2020, 20(58):1-464. doi:10.4193/Rhin20.600. [27] Han L, Shen WJ, Bittner S, et al. PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α[J]. Future Cardiol. 2017,13(3):279-296. doi:10.2217/fca-2016-0059. [28] Caillaud M, Patel NH, Toma W, et al. A fenofibrate diet prevents paclitaxel-induced peripheral neuropathy in mice[J]. Cancers, 2020, 13(1): 69. doi:10.3390/cancers13010069. [29] Liu X, Qian D, Liu H, et al. Genetic variants of the peroxisome proliferator-activated receptor(PPAR)signaling pathway genes and risk of pancreatic cancer[J]. Mol Carcinog, 2020,59(8):930-939. doi:10.1002/mc.23208. [30] Brunetti L, Loiodice F, Piemontese L, et al. New approaches to cancer therapy: combining fatty acid amide hydrolase(FAAH)inhibition with peroxisomeproliferator-activated receptors(PPARs)activation[J]. J Med Chem, 2019, 62(24): 10995-11003. doi:10.1021/acs.jmedchem.9b00885. [31] Halstead AM, Kapadia CD, Bolzenius J, et al. Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation[J]. Elife, 2017,6: e30862. doi:10.7554/eLife.30862. [32] Yi M, Tan Y, Wang L, et al. TP63 links chromatin remodeling and enhancer reprogramming to epidermal differentiation and squamous cell carcinoma development[J]. Cell Mol Life Sci, 2020,77(21):4325-4346. doi:10.1007/s00018-020-03539-2. [33] 郑雪. TP63基因启动子DNA甲基化与宫颈癌的相关性研究[D]. 唐山: 华北理工大学, 2020. [34] 魏涛,朱精强. p53 基因家族与甲状腺癌的相关研究进展[J]. 中国普外基础与临床杂志,2019, 26(11):1372-1377. doi:10.7507/1007-9424.201906054. WEI Tao, ZHU Jingqiang. Advances of relationship between p53 gene family and thyroid cancer. Chinese Journal of Bases and Clinics in General Surgery, 2019, 26(11):1372-1377. doi:10.7507/1007-9424.201906054. [35] 冯志寅, 王维娜, 董娟娟, 等. P53、P63、Ki67分子标记物与食管癌淋巴结转移相关性Logistic回归分析[J]. 新疆医科大学学报, 2015,38(9): 1091-1094,1098. doi:10.3969/j.issn.1009-5551.2015.09.007. FENG Zhiyin, WANG Weina, DONG Juanjuan, et al. Logistic regression analysis on relationship between P53 P63 Ki67 expression and lymph node metastasis in esophageal carcinoma[J]. J Xinjiang Med Univ, 2015,38(9): 1091-1094,1098.doi:10.3969/j.issn.1009-5551.2015.09.007. [36] 于克娜, 孙凯月, 张杰, 等. 西妥昔单抗治疗头颈部鳞状细胞癌差异表达基因的生物信息学分析[J]. 山东大学耳鼻喉眼学报, 2020,34(4): 117-124. doi: 10.6040 /j.Issn.1673-3770.0.2020.189. YU Kena, SUN Kaiyue, ZHANG Jie, et al. Analysis of differentially expressed genes during cetuximab treatment of head and neck squamous cell carcinoma using bioinformatics[J]. J Otolaryngol Ophthalmol Shandong Univ, 2020,34(4): 117-124. doi: 10.6040 /j.Issn.1673-3770.0.2020.189. |
| [1] | NIU Zijie, XIAO YangOverview,WANG Jun,MA LijinngGuidance. Progress in the surgical treatment of recurrent laryngeal papillomatosis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(4): 96-100. |
| [2] | YAN Jing, REN Xiaoyong, XIANG Li, DU Xiaoying, LI Na, LIU Xiaohong, HOU Jin. Preliminary observation of the immediate curative effect of unilateral idiopathic vocal cord palsy after electrical stimulation of the nerve [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2021, 35(3): 42-46. |
| [3] | This study aimed to compare the abnormality rate of vestibular evoked myogenic potentials(VEMPs)in patients with primary and recurrent benign paroxysmal positional vertigo(BPPV)and test the hypothesis that otolith dysfunction causes the recurrence of BPPV. MethodsCervical VEMP(cVEMP)and ocular VEMP(oVEMP)tests using air-conducted 500 Hz tone-burst stimuli were performed on 57 patients with unilateral primary BPPV(n=36)and recurrent BPPV(n=21)between June 2019 and May 2020. Abnormalities in cVEMP and oVEMP were compared between the primary and recurrent BPPV groups. Results(1) The differences in sex, the involved side, and canal between the primary and recurrent BPPV groups were not significant; however, the difference was statistically significant in terms of age; (2) Of the 57 BPPV patients, cVEMP or oVEMP was not elicited in 21 cases(36.84%)and 35 cases(61.40%), respectively. The abnormality rate of oVEMP was much higher(P<0.05); (3)Abnormal cVEMP was observed in 16 of 36(44.45%)and 5 of 21(23.81%)cases in the primary and recurrent BPPV groups, respectively. Abnormal oVMEP was observed in 19 of 36(52.79%)and 16 in 21(76.19%)patients in the primary and recurrent BPPV groups, respectively. Differences in the abnormality rates of cVMEP and oVMEP were not found between the primary and recurrent BPPV groups(P>0.05); (4) When the recurrent BPPV group was further divided into 2-times groups and ≥3-times group according to the recurrent frequency, there were also no statistical differences in the VEMP abnormality rate in these three groups(P>0.05). ConclusionThe results showed no significant difference in the abnormality rate of cVEMP and oVEMP between the primary BPPV and recurrent BPPV groups, indicating that the possible recurrent mechanism of primary BPPV still needs to be further studied.. Abnormality rate of vestibular evoked myogenic potentials in patients with primary and recurrent benign paroxysmal positional vertigo: a clinical observation [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(5): 51-55. |
| [4] | ObjectiveThe aim of this study was to provide new perspectives and targets for the treatment of HNSCC by screening differentially expressed genes during cetuximab treatment of head and neck squamous cell carcinoma(HNSCC)using bioinformatics. MethodsThe chip dataset, GSE109756, was downloaded from the GEO database, and the online analysis tool, GEO2R, was used to screen differentially expressed genes in head and neck squamous cell carcinoma tissues treated with and without cetuximab. The DAVID 6.8 and STRING online software were used to analyze the function of the differentially expressed genes, their pathway enrichment, and their protein interactions. Cytoscape was used to visualize and analyze the protein interactions. The online analysis tool, X2K, was used to find the transcription factors, the kinases of differentially expressed genes, and their mutual regulatory relationship with the targeted genes. ResultsNinety-one differentially expressed genes, including 50 up-regulated and 41 down-regulated genes(P<0.05; | logFC | > 1), were found in head and neck squamous cell carcinoma tissues treated with and without cetuximab. The GO and KEGG pathway analyses suggested that these differentially expressed genes were mainly enriched with immunomodulation, extracellular matrix, and other processes. Through the construction of a protein-protein interaction network, we screened CD163, VSIG4, and 3 other core differentially expressed genes(P<0.05), which were up-regulated after cetuximab treatment. In addition, our analysis shows that transcription factors, including SUZ12, TP63, and ESR1, played a key role in cetuximab treatment(P<0.05)and MAPK14, CDK1, and MAPK1 were the most important kinases during the process(P<0.05). ConclusionCD163, VSIG4, and the aforementioned transcription factors and protein kinases may be involved in the biological processes that underlie cetuximab treatment of HNSCC. This study provides new perspectives to facilitate further understanding of the biological mechanism that underlies cetuximab treatment of HNSCC and the exploration of the effectiveness of HNSCC treatment.. Analysis of differentially expressed genes during cetuximab treatment of head and neck squamous cell carcinoma using bioinformaticsYU Kena1, SUN Kaiyue2, ZHANG Jie1, JIN Peng1 1. Department of Otorhinolaryngology & Head and Neck Surgery, The Second Hospital of Shandong University, Jinan 250033, Shandong, China; 2. Shandong Provincial Otorhinolaryngology Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250022, Shandong, ChinaAbstract: [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(4): 117-124. |
| [5] | PAN Xiaofei, WANG Jun, XIAO Yang, MA Lijing. Effects of lncRNA CTB-147C22.8 and mRNA KLK6 on the invasion of recurrent respiratory papilloma cells [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(4): 66-70. |
| [6] | Wenbin LEI,Qihong LIU. Progress in the treatment of recurrent respiratory papillomatosis using a CO2 laser [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2018, 32(6): 8-12. |
| [7] | Dayu LIU,Ruijie SUN,Xuexin LI,Zhen JIANG,Jianlin YUE,Yun LIN,Dapeng LEI,Xinliang PAN. Therapeutic effect of partial laryngectomy with CO2 laser in the treatment of bilateral vocal cord paralysis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2018, 32(6): 18-21. |
| [8] | WANG Zhixiang, XUE Kai, WEI Ning, HAN Shuang, JIN Chunshun.. A case of recurrent laryngeal nerve schwannoma misdiagnosed as a thyroid tumor. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(6): 33-35. |
| [9] | ZHANG Zhuan, LIU Tao, ZHOU Changming, MA Lu. Intrathoracic vagal goiter: a report of one case and a literature review. [J]. J Otolaryngol Ophthalmol Shandong Univ, 2017, 31(6): 36-38. |
| [10] | LÜ Zhenghua. Decompression of recurrent nerve. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(2): 17-19. |
| [11] | DU Zhihong, YU Yafeng.. Effect of NLRP3 inflammasome in the pathogenesis and relapse of eosinophilic nasal polyps. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(1): 31-35. |
| [12] | FENG Yun, YANG Dazhang, LÜ Qiuping, LIU Dandan, WANG Naya. Reinnervation vesus non-reinnervation surgery for vocal fold paralysis [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(3): 54-58. |
| [13] | FENG Yun, YANG Da-zhang, CHENG Jing-ning, WANG Cheng-yuan, LIU Dan-dan. Relationship between procedures and complications in thyroid surgery [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2015, 29(1): 78-82. |
| [14] | ZHUANG Da-yong, HE Qing-qing, FAN Zi-yi, ZHENG Lu-ming, ZHU Jian, ZHOU Peng, DUAN Song-jian, YUE Tao, DONG Xue-feng. Intra-operative nerve monitoring in re-operation for differentiated thyroid carcinoma [J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(6): 5-8. |
| [15] | WANG Wei-zhi1, ZHANG Bing-feng2, LIU Shao-hua1, WANG Xin2. The clinical efficacy of systemic corticosteroids and thalidomide for oropharyngeal major recurrent aphthous ulcer [J]. J Otolaryngol Ophthalmol Shandong Univ, 2013, 27(6): 72-73. |
|